Shionogi & Co., Ltd. (塩野義製薬株式会社) is a research-driven pharmaceutical company headquartered in Osaka, Japan. The company discovers, develops, manufactures, and commercializes prescription medicines and related healthcare products, with operations in Japan, the United States, Europe, and Asia.
Shionogi’s core strengths are in infectious diseases, including antivirals and antibiotics. Notable contributions include discovery of the integrase inhibitor dolutegravir (marketed in combination regimens by ViiV Healthcare, a GSK–Pfizer–Shionogi affiliate) and the siderophore cephalosporin cefiderocol for difficult-to-treat Gram-negative infections. The company also develops therapies in areas such as pain/CNS and metabolic disorders, and it advances small-molecule antiviral programs such as ensitrelvir (Xocova) for COVID‑19 in Japan. Beyond R&D, Shionogi supports global supply through active pharmaceutical ingredient and finished dosage manufacturing, alongside partnerships and licensing that extend the reach of its technologies.
None yet. When a new project in the record names Shionogi as owner, partner or investor, it shows here.
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.
